Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206469 | 0.90 | ACSS2 (0.45) | KDM4EACSS2TLR7TLR8 | |
| SCHEMBL25089560 | 0.85 | CNR2 (0.49) | KDM4EACSS2TLR7NPC1RAB9A | |
| SCHEMBL1637611 | 0.83 | AGTR1 (0.53) | ACSS2TLR7 | |
| SCHEMBL1638544 | 0.83 | MAPT (0.54) | KDM4EACSS2TLR7TLR8 | |
| SCHEMBL1638170 | 0.79 | MAPT (0.40) | KDM4ETLR7NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15510198 | 0.77 | AGTR1 (0.51) | ALDH1A1ACSS2 | |
| SCHEMBL30676114 | 0.77 | ACSS2 (0.46) | KDM4ELMNAACSS2NPC1RAB9A | |
| SCHEMBL20266433 | 0.77 | ACSS2 (0.46) | KDM4ELMNAACSS2NPC1RAB9A | |
| SCHEMBL1637212 | 0.77 | MAPT (0.45) | TLR7TLR8NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1206622 | 0.75 | MAPT (0.56) | KDM4EALDH1A1LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | KDM4E 2406/4885ALDH1A1 2045/4885LMNA 4136/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | KDM4E 2871/4885ALDH1A1 1901/4885LMNA 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.